Related Experiment Video
Updated: Mar 18, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
MET Expressed in Glioma Stem Cells Is a Potent Therapeutic Target for Glioblastoma Multiforme
Takayuki Tasaki1, Mitsugu Fujita2, Takeshi Okuda1
1Department of Neurosurgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Background:
Glioblastoma multiforme (GBM) is the most frequent and the most malignant tumor among adult brain tumors. Previous reports led us to hypothesize that the proto-oncogene mesenchymal-epithelial transition (MET) expressed in glioma stem cell-like cells (GSCs) would be a potent therapeutic target for GBM.
Patients And Methods:
To address this question, we analyzed 113 original samples of tumors from patients based on immunohistochemistry. During this process, we were able to establish GSC lines from patients with GBM that were MET-positive and MET-negative. Using these cells, we tested the therapeutic impact of a MET inhibitor, crizotinib, both in vitro and in vivo.
Results:
Patients with MET-positive GBM exhibited poor survival. GSC-based experiments revealed that treatment with crizotinib, both in vitro and in vivo, exhibited therapeutic efficacy particularly against MET-positive GSCs.
Conclusion:
Based on these findings, we conclude that MET expressed in GSCs might be a potent therapeutic target for GBM.
